Probing the Proteome for Atrial Fibrillation
- PMID: 40720559
- DOI: 10.1161/CIRCULATIONAHA.125.075341
Probing the Proteome for Atrial Fibrillation
Keywords: Editorials; arrhythmias, cardiac; atrial fibrillation; proteome.
Conflict of interest statement
Drs Patel and Ruff are members of the TIMI Study Group, which has received institutional research grant support through Brigham and Women’s Hospital from Abbott, Amgen, Anthos Therapeutics, ARCA Biopharma, Inc, AstraZeneca, Bayer HealthCare Pharmaceuticals, Inc, Daiichi-Sankyo, Eisai, Intarcia, Ionis Pharmaceuticals, Inc, Janssen Research and Development, LLC, MedImmune, Merck, Novartis, Pfizer, Quark Pharmaceuticals, Regeneron Pharmaceuticals, Inc, Roche, Siemens Healthcare Diagnostics, Inc, Softcell Medical Limited, The Medicines Company, and Zora Biosciences. Dr Patel reports consulting fees from Janssen. Dr Ruff reports honoraria from Altimmune, Anthos, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Merck, and Pfizer.
Comment on
-
Proteomic Signatures for Risk Prediction of Atrial Fibrillation.Circulation. 2025 Jul 29;152(4):217-229. doi: 10.1161/CIRCULATIONAHA.124.073457. Epub 2025 May 22. Circulation. 2025. PMID: 40401370
Publication types
LinkOut - more resources
Full Text Sources